Cue Biopharma, Inc. Long-Term Debt
Cue Biopharma, Inc. (CUE) had Long-Term Debt of $0 as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermDebtNoncurrent · last filed 2025-03-31
- 2024-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2024-09-30: Long-term Debt, Excluding Current Maturities $1.33M.
- 2024-06-30: Long-term Debt, Excluding Current Maturities $2.29M.
- 2024-03-31: Long-term Debt, Excluding Current Maturities $3.24M.
| Period end | Long-term Debt, Excluding Current Maturities | Long-term Debt, Excluding Current Maturities as first filed |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-31 | |
| 2024-09-30 | $1.33M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $2.29M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $3.24M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $4.20M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $5.16M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $6.12M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $7.08M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $8.04M 10-K · filed 2024-03-28 | $8.03M 10-K · filed 2023-03-21 |
| 2022-09-30 | $8.99M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $9.91M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $9.86M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |